Trump signs order to boost domestic pharma manufacturing

Trump’s healthcare executive order could be a win for pharma

On April 15, President Trump signed a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged by middlemen, and limit Medicare payments for outpatient services provided by hospitals.

April 18, 2025

Vol.51 No.15

Podcast

In The Headlines: How tariffs could cause direct harm to patients

In this episode of the Cancer Letter Podcast, all three of The Cancer Letter’s reporters come together to talk about the potential impact of President Donald Trump’s tariffs on cancer care.

March 26, 2025

Vol.51 No.11

Clinical Trials & Tribulations

Better oncology drug management could lead to improved outcomes, lower costs

Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.

July 26, 2024

Vol.50 No.30

By Matt Ingram

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

Scripius and Avera collaborate to reduce prescription costs

Scripius, a Utah-based Pharmacy Benefit Management, or PBM, service, and Avera formed a collaboration aimed at reducing prescription costs. Scripius will serve as the PBM for approximately 80,000 Avera Health Plans members.

April 05, 2024

Vol.50 No.14

Guest Editorial

Turning the page: Projections for cancer care in the coming year

As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers.

December 08, 2023

Vol.49 No.45

By Samyukta Mullangi

Trump signs order to boost domestic pharma manufacturing

YOU MAY BE INTERESTED IN

Trump’s healthcare executive order could be a win for pharma

In The Headlines: How tariffs could cause direct harm to patients

Better oncology drug management could lead to improved outcomes, lower costs

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Scripius and Avera collaborate to reduce prescription costs

Turning the page: Projections for cancer care in the coming year

Renew today!

Subscriber content

Never miss an issue!

Login

Trump signs order to boost domestic pharma manufacturing

YOU MAY BE INTERESTED IN

Trump’s healthcare executive order could be a win for pharma

In The Headlines: How tariffs could cause direct harm to patients

Better oncology drug management could lead to improved outcomes, lower costs

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Scripius and Avera collaborate to reduce prescription costs

Turning the page: Projections for cancer care in the coming year

Never miss an issue!

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”